Free Trial
NYSEAMERICAN:NBY

NovaBay Pharmaceuticals (NBY) Stock Price, News & Analysis

$0.14
+0.01 (+7.63%)
(As of 05/28/2024 ET)
Today's Range
$0.13
$0.15
50-Day Range
N/A
52-Week Range
$0.07
$1.28
Volume
9.19 million shs
Average Volume
6.88 million shs
Market Capitalization
$593,610.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
NBY stock logo

About NovaBay Pharmaceuticals Stock (NYSEAMERICAN:NBY)

NovaBay Pharmaceuticals, Inc. develops and sells eyecare and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; Avenova Eye Health Support antioxidant-rich oral supplements; Avenova Lubricating Eye Drops for instant relief; NovaWipes by Avenova; Avenova WarmEye Compress to soothe the eyes; and the i-Chek by Avenova to monitor physical eyelid health. The company also provides wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. It sells its products through the company's web stores, third-party online retailers and distribution partners. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.

NBY Stock Price History

NBY Stock News Headlines

Q4 2023 NovaBay Pharmaceuticals Inc Earnings Call
NovaBay Pharmaceuticals Inc.
NovaBay Pharmaceuticals, Inc. (NBY)
Recap: NovaBay Pharmaceuticals Q3 Earnings
NovaBay Pharmaceuticals: CEO Interview
Why NovaBay Pharmaceuticals Stock Is Blasting Higher
See More Headlines
Receive NBY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NovaBay Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/09/2024
Today
5/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NYSEAMERICAN:NBY
Employees
24
Year Founded
N/A

Profitability

Net Income
$-10,610,000.00
Pretax Margin
-79.70%

Debt

Sales & Book Value

Annual Sales
$14.40 million
Book Value
$1.53 per share

Miscellaneous

Free Float
4,160,000
Market Cap
$593,610.00
Optionable
Not Optionable
Beta
2.82
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. Justin M. Hall Esq. (Age 46)
    President, CEO, General Counsel, Chief Compliance Officer, Corporate Secretary & Director
    Comp: $364.15k
  • Mr. Tommy Law (Age 39)
    Controller, Interim CFO & Treasurer
    Comp: $177.7k

NBY Stock Analysis - Frequently Asked Questions

How have NBY shares performed in 2024?

NovaBay Pharmaceuticals' stock was trading at $0.1802 at the start of the year. Since then, NBY stock has decreased by 21.8% and is now trading at $0.1410.
View the best growth stocks for 2024 here
.

Are investors shorting NovaBay Pharmaceuticals?

NovaBay Pharmaceuticals saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 30,500 shares, a decline of 77.7% from the April 30th total of 137,000 shares. Based on an average trading volume of 8,110,000 shares, the days-to-cover ratio is currently 0.0 days. Approximately 0.1% of the company's stock are short sold.
View NovaBay Pharmaceuticals' Short Interest
.

How were NovaBay Pharmaceuticals' earnings last quarter?

NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) announced its earnings results on Thursday, May, 9th. The biopharmaceutical company reported ($0.14) EPS for the quarter. The biopharmaceutical company had revenue of $2.63 million for the quarter. NovaBay Pharmaceuticals had a negative trailing twelve-month return on equity of 146.20% and a negative net margin of 79.70%.

When did NovaBay Pharmaceuticals' stock split?

Shares of NovaBay Pharmaceuticals reverse split before market open on Wednesday, November 16th 2022. The 1-35 reverse split was announced on Wednesday, November 16th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 16th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of NovaBay Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NovaBay Pharmaceuticals investors own include Aeterna Zentaris (AEZS), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Bionano Genomics (BNGO), Heat Biologics (HTBX), iBio (IBIO), Matinas BioPharma (MTNB), Novan (NOVN), ADMA Biologics (ADMA) and Vaxart (VXRT).

How do I buy shares of NovaBay Pharmaceuticals?

Shares of NBY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSEAMERICAN:NBY) was last updated on 5/29/2024 by MarketBeat.com Staff

From Our Partners